Company News

Aug 04, 2008

Lentigen, Invitrogen to Provide Lentivirus Products and Services for Gene Over-Expression

CARLSBAD, Calif. & BALTIMORE-- Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and Lentigen Corporation, a privately-held biotechnology company specializing in the development and manufacture of lentivira Read More...

Filed Under: Company News

Jul 17, 2008

APMA Announces HyperMed's New Technology Predicts Healing Potential of Diabetic Ulcers - May Prevent Devastating Diabetic Limb Amputations

Burlington, MA – July 17, 2008 – Today the American Podiatric Medical Association (APMA) announced that HyperMed's OxyVu™ imaging system may predict healing of diabetic ulcers. OxyVu™ uses proprietary technology pioneered by HyperMed in the first medical application of Read More...

Filed Under: Company News

Jun 15, 2008

Lentigen Corporation Receives Four Research Grants from the National Institute of Health

Baltimore, MD (May 15, 2008) – Lentigen Corporation announced today that it has received four National Institutes of Health (NIH) small business innovation research (SBIR) grants to collaborate with leading scientists. Through these grants, Lentigen will Read More...

Filed Under: Company News

Apr 21, 2008

Mark B. Carbeau Appointed Director, Chief Executive Officer and President of HyperMed, Inc, Daniel J. Levangie To Serve as Chairman of the Board of Directors

Burlington, MA – April 21, 2008 – HyperMed, Inc., the developer and manufacturer of hyperspectral diagnostic systems with application in diabetic and vascular disease, today announces the appointment of Mark B. Carbeau as Director, Chief Executive Officer, and President, effective Read More...

Filed Under: Company News

Apr 03, 2008

Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge

BALTIMORE, April 3, 2008 /PRNewswire/ -- Lentigen Corporation today announced an exclusive licensing agreement with Cambridge Enterprise, the organization responsible for licensing technologies from the University of Cambridge (U.K.), for a fundamental patent in the area of lentiviral vec Read More...

Filed Under: Company News

Mar 25, 2008

Lentigen, WARF, and UW-Madison Influenza Researcher Agree to Donate Technology from Joint Project Supported by Bill & Melinda Gates Foundation

The University of Wisconsin-Madison has received a $1.3 million grant from the Bill & Melinda Gates Foundation to support research aimed at understanding the molecular features that lead to influenza pandemics. UW-Madison will collaborate with Maryland-based Lentigen Corp. on the project. Read More...

Filed Under: Company News

Mar 20, 2008

Lentigen Corporation Announces Exclusive Licensing Agreement with Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer

Gaithersburg, MD ( March 20, 2008) – Lentigen Corporation today announced an exclusive licensing agreement with Case Western Reserve University (CWRU) in Cleveland, Ohio, to develop a novel stem-cell therapy for glioblastoma, an aggressive type of brain cancer. Under Read More...

Filed Under: Company News

Feb 13, 2008

Lentigen to Move Headquarters and Manufacturing to Gaithersburg

Gaithersburg, MD (February 13, 2008) – Lentigen Corporation today announced the company is moving its corporate headquarters and manufacturing facilities from the University of Maryland Baltimore County TechCenter to a new 26,000 square-foot facility in Gaithersburg. Read More...

Filed Under: Company News

Jan 28, 2008

Lentigen Appoints Tim Ravenscroft as Chief Executive Officer

BALTIMORE, Jan. 28 /PRNewswire/ -- Lentigen Corporation today announced the appointment of Tim Ravenscroft as chief executive officer. David Wetherell, Lentigen's chairman, commented, "The board of Lentigen is delighted that Tim has agreed to Read More...

Filed Under: Company News

Jan 25, 2008

HyperMed receives 510K approval to market its second-generation device, OxyVu-2 for use in determining oxygenation levels in tissue for patients with potential circulatory compromise

Burlington, MA – January 25, 2008 – HyperMed has just received U.S. Food and Drug Administration (FDA) approval to legally market its second-generation diagnostic device, the OxyVu™-2. The non-invasive OxyVu™-2 Hyperspectral Tissue Oxygenation Measurement System (HTCOM Read More...

Filed Under: Company News

35 results:

1234>>